




# Sex/gender considerations in research on cognitive ageing and dementia

Prof. Anja Leist, University of Luxembourg  
19 December 2024



European Research Council  
Established by the European Commission

# First things first: Thanks to team and collaborators




## Team

Katherine Ford  
Ivana Paccoud  
Fabiana Ribeiro  
Matthias Klee  
Anouk Geraets  
Jung Hyun Kim  
Ana Carolina Teixeira Santos  
Melissa Chan  
Jure Mur  
Laure Pauly


## Main collaborators

Rejko Krüger  
Paul Wilmes  
Patrick May  
Lindsay Kobayashi  
David Llewellyn  
Kenneth M. Langa  
Graciela Muniz-Terrera  
Sara Wade  
M. Maria Glymour  
Ariane Bertogg  
Johan Rehnberg  
David Batty  
James Nazroo  
Martin Rossor  
Marc Suhrcke  
Jean-Paul Steinmetz

# The course of cognitive decline - inevitable?



## The continuum of Alzheimer's disease



- Globally, more than 55 million people living with dementia, with an additional 10 million newly affected each year<sup>1</sup>
- 2023: First drugs to slow cognitive decline or improve ADLs received FDA approval<sup>3</sup>

Figure credit: DOI: 10.2217/bmm.14.42

<sup>1</sup><https://www.who.int/news-room/fact-sheets/detail/dementia>

<sup>2</sup>10.14283/jpad.2024.37

# Neurodegenerative disease burden



- Age as strongest risk factor of neurodegenerative diseases.<sup>1</sup>
- Annual societal costs of dementia estimated at US \$1313.4 billion for 55.2 million people with dementia in 2019 globally.<sup>2</sup>
- Modifiable factors in dementia estimated to contribute 40%, while genetic risk contributes ca. 7%.<sup>3</sup>
- Prevention, particularly primordial, safer and likely to be more cost-effective

<sup>1</sup> Hou et al. 2019. doi: 10.1038/s41582-019-0244-7

<sup>2</sup> Wimo et al. 2023. doi: 10.1002/alz.12901

<sup>3</sup> Livingston et al. 2020. doi: 10.1016/S0140-6736(20)30367-6




Figure: Hou et al. 2019. doi: 10.1038/s41582-019-0244-7

# Inequalities in research on neurodegenerative diseases

Less research funding on conditions affecting women more often or exclusively

Lower enrollment of women in drug trials on neurodegenerative diseases

## Sex/gender inequalities in research on and treatment of medical conditions



Less knowledge on presentation of symptoms of disease in women

Less knowledge on response to treatment and quality of care outcomes in women

Similar symptom presentation (e.g. pain reports) shows sex/gender differences in treatment, referrals

# Sex/gender differences in prevalence of and disability resulting from brain diseases

**Stroke:** Second leading cause of death, leading cause of disability. Women bear 55% of global burden (f/m prevalence: 1,463 vs. 1,160 per 100,000)

**Dementia:** 55m people today; 139m in 2050. Women bear two thirds of global burden. Women account for 60% of AD caregivers.

**Parkinson's Disease:** Over 8m people: 4.6m men and 3.8m women. More disabling for men than women (f/m DALYs: 68 vs. 94 per 100,000).

**Multiple Sklerosis:** 2.8m people; most common disabling neurological disease in young people. Women bear two thirds of global burden (f/m prevalence: 31 vs. 15 per 100,000)

**Migraine:** Second-most disabling condition (1st: back pain). 1.04bn people. Women have 2-3 times higher risk of migraine. More disabling for women (f/m DALYs 685 vs. 403 per 100,000).



# Accountability of sex and gender in health research

## Policy & practice

### Differentiating sex and gender in health research to achieve gender equity

Michelle R Kaufman,<sup>a</sup> Evan L Eschliman<sup>a</sup> & Tahilin Sanchez Karver<sup>a</sup>

**Abstract** Effectively tracking progress on initiatives focused on gender equity requires clear differentiation between the terms sex and gender. Sex usually refers to a person's biological characteristics, whereas gender refers to socially constructed roles and norms. Although both terms are often treated as binaries, gender is a spectrum and sex may include intersex individuals. While the terms are interrelated, are sometimes conflated or used interchangeably in health data. Their fundamental distinctions, however, have implications for the conduct of research and the design of interventions targeting sex- and gender-based health disparities. We use the example of coronavirus disease 2019 to show how conflating these terms in data collection makes it difficult to ascertain whether disparities in infection rates, morbidity and mortality are determined by sex or gender. Although the exact process of collecting data on sex and gender may need to be adapted for specific contexts, there are steps that can be taken so that health data better reflect the differences between these concepts. Possible actions include using a two-step data collection process to determine both sex and gender of individuals, and encouraging recognition of intersex, third gender, transgender and gender nonbinary people. There also needs to be acceptance and commitment by data collectors and research editors; for example, by using tools such as the Sex and Gender Equity in Research checklist. With clearer distinctions between these foundational terms and how they are used in health data, we can achieve more accurate research findings, better-tailored interventions and better progress towards gender equity.

doi: 10.2471/BLT.22.289310; doi: 10.1016/j.outlook.2024.102194



Nursing Outlook  
Volume 72, Issue 4, July–August 2024, 102194



## Ensuring accountability for consideration of sex as a biological variable in research

Elizabeth A. Kostas-Polston PhD, FAANP, FAAN <sup>a,1</sup> ✉, Margaret Bevens PhD, RN, FAAN <sup>b,1</sup>, Tamra L. Shea PhD, RN, CNE <sup>c</sup>, Kelly McGlothen-Bell PhD, RN, FAWHONN <sup>d</sup>, Mary A. Nies PhD, FAAN, FAAHB <sup>e</sup>, Ivy M. Alexander PhD, FAANP, FAAN <sup>f</sup>, Versie Johnson-Mallard PhD, FAANP, FAAN <sup>g</sup>, Janine Austin Clayton MD, FARVO <sup>h</sup>

Show more ▾

+ Add to Mendeley Share Cite

<https://doi.org/10.1016/j.outlook.2024.102194>

[Get rights and content](#)

### Highlights

- Omics-based clinical discoveries explain the influences of sex and gender on health and disease.
- Despite consensus that sex and gender are distinct constructs, their use in research is unreliable.



# The role of context and the social determinants of health

- Socioeconomic inequalities, i.e. deprivation
- Inequality of educational opportunity
- Gender inequalities




# The role of schooling

Participants to the Survey of Health, Ageing and Retirement in Europe: 25,544 women, 20,904 men with 2-6 assessments, three 10-year birth cohorts born after 1940

Cognition: Immediate and delayed recall, verbal fluency

Inequality of educational opportunity data from the World Bank Global Database on Intergenerational Mobility

Controlling for range of contextual- and individual-level confounders



Associations of level of IEO on level of and rate of change in three cognitive measures in stratified multilevel (mixed-effects) models.

	Women			Men		
	Immediate recall	Delayed recall	Verbal fluency	Immediate recall	Delayed recall	Verbal fluency
	Coeff. (CI)	Coeff. (CI)	Coeff. (CI)	Coeff. (CI)	Coeff. (CI)	Coeff. (CI)
(Intercept)	-0.27 *** (-0.34 to -0.19)	-0.20 *** (-0.28 to -0.12)	-0.29 *** (-0.39 to -0.19)	-0.30 *** (-0.37 to -0.19)	-0.26 *** (-0.33 to -0.19)	-0.25 *** (-0.35 to -0.16)
IEO	-1.23 ** (-1.97 to -0.48)	-0.97 * (-1.78 to -0.16)	-1.77 ** (-2.84 to -0.70)	-0.94 ** (-1.50 to -0.38)	-0.60 (-1.20 to -0.00)	-1.79 *** (-2.74 to -0.84)
IEO*age	0.17 * (0.02-0.32)	-0.17 * (-0.32 to -0.02)	-0.39 *** (-0.53 to -0.24)	0.48 *** (0.32-0.65)	0.01 (-0.16 - 0.18)	-0.16 (-0.32 - 0.01)



Leist, A. K., Bar-Haim, E., & Chauvel, L. (2021). Inequality of educational opportunity at time of schooling predicts cognitive functioning in later adulthood. *SSM - Population Health*, doi: 10.1016/j.ssmph.2021.100837

# The role of modifiable risk factors in cognitive ageing and dementia








Illustration credit: doi:  
10.1016/S0140-6736(20)30367-6

# Sex/gender and socioeconomic differences in modifiable risk factors for dementia



Dr. Anouk Geraets

# Sex/gender and socioeconomic differences in modifiable risk factors for dementia

Sex/gender and socioeconomic differences in dementia and modifiable risk factors for dementia

*Different risk factor prevalence or different exposure-outcome relationships?*

English Longitudinal Study of Ageing (2008/2009 to 2018/2019)

N = 8,941 individuals, mean age,  $66.1 \pm 9.8$  years; n = 4,935 (55.2%) women

Modifiable risk factors according to the LIBRA score.

# Sex/gender and socioeconomic differences in modifiable risk factors for dementia

- No overall sex/gender difference in dementia risk
- Dementia risk was higher among those with
  - Childhood deprivation [hazard ratio (HR) = 1.51 (1.17; 1.96)];
  - Lower occupational attainment [HR low versus high = 1.60 (1.23; 2.09) and HR medium versus high = 1.53 (1.15; 2.06)];
  - Low wealth [HR low versus high = 1.63 (1.26; 2.12)].

# Sex/gender and socioeconomic differences in modifiable risk factors for dementia

- Sex/gender differences in modifiable risk factors
  - Low cognitive activity was associated with a higher dementia risk for women [HR = 2.61 (1.89; 3.60)] compared to men [HR = 1.73 (1.20; 2.49)].
- No consistent socioeconomic differences in modifiable dementia risk factors.

⇒ Preference for population-based approach that tackles inequalities and modifiable risk factor burden directly, compared to individual approaches in dementia prevention.





# Sex/gender differences in (modifiable) risk burden and dementia risk

Dr. Fabiana Ribeiro

- Meta-analysis: Increased dementia risk in women due to higher life expectancy and fewer educational and occupational opportunities in Latin America; further vulnerable groups low-educated and rural residents <sup>1</sup>
- Framework for identifying how gender inequalities translate into elevated dementia risk in women in Latin American countries<sup>2</sup>

<sup>1</sup>Ribeiro, F., Teixeira-Santos, A. C., Caramelli, P., & Leist, A. K. (2022). Systematic review and meta-analyses on the prevalence of dementia in Latin America and Caribbean countries: Exploring sex, rurality, age, and education as possible determinants. *Aging Research Reviews*, 81, 101703. doi: 10.1016/j.arr.2022.101703

<sup>2</sup>Ribeiro, F., Crivelli, L., & Leist, A. K. (2023). Gender inequalities as contributors to dementia in Latin America and Caribbean Countries: what factors are missing from research? *The Lancet Healthy Longevity*. [https://doi.org/10.1016/S2666-7568\(23\)00052-1](https://doi.org/10.1016/S2666-7568(23)00052-1)







Figure © Ribeiro et al. (2023), doi.org/10.1016/S2666-7568(23)00052-1




# The role of glycemia in menopausal factors


## Dr. Anouk Geraets

- Age at natural menopause, occurrence of bilateral oophorectomy, hysterectomy and age at surgery (n=147,119 women; mean±SD age 55.2±8.0 years at baseline)
- Glycemia assessed through fasting glucose levels and HbA1c
- Incident dementia assessed through hospital and death records




Geraets, A.F.J., Schram, M.T., Jansen, J.F.A., Köhler, S., van Boxtel, M.P.J., Eussen, S.J.P.M., Koster, A., Stehouwer, C.D.A., Bosma, H., & Leis, A.K. (2024). The associations of socioeconomic position with structural brain damage and connectivity and cognitive functioning: The Maastricht Study. *Social Science & Medicine*. <https://doi.org/10.1016/j.socscimed.2024.117111>








Early menopause (<45 years)



Bilateral Oophorectomy (BO)




Total Hysterectomy and Bilateral  
Oophorectomy (THBO)




Partial  
hysterectomy




Increased dementia risk



# Introduction



Early menopause (<45 years)





Glycaemia



Increased dementia  
risk

<https://doi.org/10.1016/j.socscimed.2024.117111>



We used data from the population-based UK Biobank cohort (n=147,119 women; mean±SD age 55.2±8.0 years at baseline; 1,385 incident dementia cases).

This study included follow-up data for dementia risk until November 6, 2021 (mean follow-up duration 12.4±1.6 years).



Enabling scientific discoveries that improve human health

<https://doi.org/10.1016/j.socscimed.2024.117111>



**Menopausal factors:** menopausal status, bilateral oophorectomy, hysterectomy, and age at menopause or surgery were self-reported.

Age was treated as both a continuous and categorical variable (<45 years of age).

**Markers of glycemia:** baseline fasting plasma glucose (mmol/L) and hemoglobin A1c (HbA1c; mmol/mol) levels standardized into z-scores.

**Dementia:** dementia diagnosis was ascertained from hospital records until 06-11-2021.

- Stata 18.
- Cox proportional hazard regression analyses tested the associations between menopausal factors and dementia risk.
- Linear regression analyses tested the associations of menopausal factors with glycemia.
- Causal mediation was tested using the mediate command. Age at natural or surgical menopause was standardized and a standard deviation of +1 was compared to a standard deviation of -1.
- All analyses were adjusted for age at baseline, educational attainment, and history of hormone replacement therapy.
- A two-sided p-value  $<0.05$  was considered statistically significant.

# Results – Characteristics of study population

Characteristic	Incident dementia	
	No (n=145,734)	Yes (n=1,385)
<b>Demographics</b>		
Age (years)	<b>55.1 ± 8.0</b>	<b>63.7 ± 5.3</b>
High educational attainment, n (%)	<b>60,588 (41.6)</b>	<b>467 (33.7)</b>
<b>Menopausal factors</b>		
Pre-menopausal, n (%)	<b>46,260 (31.7)</b>	<b>51 (3.7)</b>
Natural menopause, n (%)	<b>82,699 (58.0)</b>	<b>1,072 (82.0)</b>
Bilateral oophorectomy, n (%)	9,730 (6.7)	109 (7.9)
Hysterectomy, n (%)	<b>3,816 (2.6)</b>	<b>75 (5.4)</b>
Age natural menopause (years)	50.3 ± 4.5	50.0 ± 5.0
Early natural menopause (< 45 years), n (%)	7,579 (9.2)	111 (10.7)
Age bilateral oophorectomy (years)	45.7 ± 6.7	46.2 ± 7.2
Early bilateral oophorectomy (< 45 years), n (%)	3,510 (36.6)	35 (34.7)
Age hysterectomy (years)	41.4 ± 6.4	41.5 ± 7.6
Early hysterectomy (< 45 years), n (%)	2,578 (68.5)	55 (74.3)
Ever used hormone replacement therapy, n (%)	49,065 (33.7)	779 (56.3)
<b>Glycemia</b>		
Fasting plasma glucose (mmol/L)	<b>5.0 ± 1.0</b>	<b>5.3 ± 1.5</b>
HbA1c (mmol/mol)	<b>35.4 ± 5.6</b>	<b>38.0 ± 8.5</b>

Data are presented as means ± standard deviation or number (%). HbA1c indicates hemoglobin A1c; HDL, high-density lipoprotein.

Statistically significant associations using a two-sided *p*-value < 0.05 are presented in bold.

# Results 1 – Menopausal factors and glycaemia with dementia risk


	Incident dementia HR (95% CI)	p-value
<b>Menopausal factors</b>		
Bilateral oophorectomy aged ≥ 50 years <sup>a</sup> (n=95,710)	0.87 (0.71;1.06)	0.169
Hysterectomy aged ≥ 50 years <sup>a</sup> (n=90,719)	1.10 (0.86;1.39)	0.449
Age natural menopause (years) (n=82,406)	<b>0.97 (0.96;0.98)</b>	<b>&lt;0.001</b>
Early natural menopause (n=82,406)	<b>1.32 (1.08;1.60)</b>	<b>0.006</b>
Age bilateral oophorectomy (years) (n=9,687)	0.97 (0.95;1.00)	0.063
Early bilateral oophorectomy (n=9,687)	1.43 (0.95;2.17)	0.089
Age hysterectomy (age) (n=3,837)	0.98 (0.95;1.02)	0.301
Early hysterectomy (n=3,837)	1.60 (0.95;2.71)	0.079
<b>Markers of glycemia</b>		
Fasting plasma glucose (per 1 SD) (n=147,119)	<b>1.15 (1.10;1.20)</b>	<b>&lt;0.001</b>
HbA1c (per 1 SD) (n=147,119)	<b>1.21 (1.16;1.26)</b>	<b>&lt;0.001</b>

n=1,254 dementia cases for bilateral oophorectomy aged ≥ 50 years, n=1,223 dementia cases for hysterectomy aged ≥ 50 years; n=1,035 dementia cases for age at natural menopause; n=101 dementia cases for age at bilateral oophorectomy; n=74 dementia cases for age at hysterectomy; n=1,385 dementia cases for glucose and HbA1c. HR indicates hazard ratio; CI, confidence interval; SD, standard deviation; HbA1c, hemoglobin A1c. Analyses are adjusted for age, educational level, and history of hormone replacement therapy. Statistically significant associations using a two-sided *p*-value < 0.05 are presented in bold. <sup>a</sup> Compared to post-menopausal women without surgical interference prior to menopause. Statistically significant associations using a two-sided *p*-value < 0.05 are presented in bold.

## Results 2 – Menopausal factors with glycaemia



Menopausal factors	Fasting plasma glucose (per 1 SD) B (95% CI)	HbA1c (per 1 SD) B (95% CI)
Bilateral oophorectomy aged < 50 years <sup>a</sup> (n=47,518)	<b>0.052 (0.002;0.101)</b>	<b>0.216 (0.166;0.267)</b>
Bilateral oophorectomy aged ≥ 50 years <sup>b</sup> (n=95,710)	0.064 (0.045;0.083)	<b>0.062 (0.043;0.081)</b>
Hysterectomy aged < 50 years <sup>a</sup> (n=46,561)	<b>-0.002 (-0.091;0.087)</b>	<b>0.140 (0.048;0.231)</b>
Hysterectomy aged ≥ 50 years <sup>b</sup> (n=90,719)	<b>0.065 (0.037;0.093)</b>	<b>0.087 (0.060;0.115)</b>
Age natural menopause (years) (n=82,406)	<b>-0.001 (-0.003;-0.000)</b>	<b>-0.003 (-0.005;-0.002)</b>
Early natural menopause (n=82,406)	<b>0.027 (0.008;0.047)</b>	<b>0.064 (0.044;0.083)</b>
Age bilateral oophorectomy (years) (n=9,687)	<b>-0.008 (-0.011;-0.005)</b>	<b>-0.006 (-0.009;-0.003)</b>
Early bilateral oophorectomy (n=9,687)	<b>0.087 (0.047;0.127)</b>	<b>0.084 (0.043;0.124)</b>
Age hysterectomy (age) (n=3,837)	<b>-0.009 (-0.014;-0.003)</b>	<b>-0.009 (-0.014;-0.004)</b>
Early hysterectomy (n=3,837)	<b>0.076 (0.007;0.146)</b>	<b>0.079 (0.009;0.150)</b>

B indicates unstandardized regression coefficient; CI, confidence interval; SD, standard deviation; HbA1c, hemoglobin A1c. Analyses are adjusted for age, educational level, and history of hormone replacement therapy. Statistically significant associations using a two-sided  $p$ -value < 0.05 are presented in bold. <sup>a</sup> Compared to pre-menopausal women without surgical interference. <sup>b</sup> Compared to post-menopausal women without surgical interference prior to menopause. Statistically significant associations using a two-sided  $p$ -value < 0.05 are presented in bold.




n=82,406. Analyses are adjusted for age, educational level, and history of hormone replacement therapy. Statistically significant associations using a two-sided  $p$ -value  $< 0.05$  are presented in bold. <sup>a</sup> Age is standardized and a standard deviation of 1 is compared to a standard deviation of -1.

# Key points



Glycaemia



Images for illustrative purposes only

Images for illustrative purposes only



HbA1c



Increased dementia  
risk



- More studies are needed to investigate alternative mechanisms like genetics, environment, inflammation, lifestyle, socioeconomic position, and comorbidities.
- Women who undergo natural menopause at a young age should be monitored for both hyperglycemia and cognitive decline.
- Addressing modifiable risk factors could have a significant protective effect against both hyperglycemia and cognitive decline and dementia.
- Interventional studies that test the effect of hormone replacement therapy should consider genetic risk for dementia.



# The role of gender-role norms and gender inequalities

- The role of gender-role attitudes: “Men should have more right to job than women when jobs are scarce”, “Women should be prepared to cut down on paid work for sake of family”, and employment biographies for later-life cognitive functioning<sup>1</sup>
- Mechanisms: work-related cognitive stimulation and multiple-role benefits
- Longer spells of both full-time and part-time employment beneficial for cognitive functioning
- For women, we find that part-time employment—as a means of reconciling family tasks and professional careers—comes with higher cognitive benefits
- Longer spells of homemaking in women are less beneficial for cognitive functioning, as are longer spells of unemployment.



<sup>1</sup>Bertogg., A., & Leist, A. K. (2023). Gendered life courses and cognitive functioning in later life: The role of gender norms and employment biographies. *European Journal of Ageing*. <https://doi.org/10.1007/s10433-023-00751-4>  
Received the Excellence prize of the EHMS and the Vontobel prize for Ageing Research, 2024.



CRISP follow-up: Societal impact generation through website, workshops, public talks in collaboration with


**GetBrainHealthy.org: Scaling Science Promotion and Brain Health Education to the Public**



Melissa Chan, Global Brain Health Institute fellow  
Dr. Laure Pauly, neuroscience specialist and science communicator



08/2024-07/2027, 399k EUR. Supported by the Luxembourg National Research Fund (FNR) under the PSP Flagship programme no. PSP/2024/18867322



# Main funding



This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (CRISP, grant agreement No. 803239).

# Affiliated projects



INSTITUTE FOR ADVANCED STUDIES (IAS)

AUDACITY-2019 MCI-BIOME, co-PIs Leist, Wilmes, Krueger



Luxembourg National Research Fund

MEDITAGING, co-funding Zitha



anja.leist@uni.lu  
 @AnjaLeist  
<https://cognitiveageing.uni.lu>